Skip to main content

Necrotizing Enterocolitis

2
Pipeline Programs
7
Companies
6
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
2
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

7 companies ranked by most advanced pipeline stage

BioTherapeutics Inc
BioTherapeutics IncVA - Blacksburg
1 program
1
ST266Phase 1/21 trial
Active Trials
NCT06315738Recruiting36Est. Nov 2029
Noveome Biotherapeutics
1 program
1
ST266Phase 1/2
Infant Bacterial Therapeutics
2 programs
IBP-9414PHASE_21 trial
IBP-9414PHASE_31 trial
Active Trials
NCT02472769Completed120Est. Aug 2017
NCT03978000Unknown2,158Est. Jul 2024
Human BioSciences
Human BioSciencesWV - Martinsburg
1 program
laparotomyN/A1 trial
Active Trials
NCT00252681Completed130Est. Jun 2005
Autonomous Therapeutics
1 program
thermostatic feedingN/A1 trial
Active Trials
NCT06908239Active Not Recruiting250Est. Dec 2029
Leadiant Biosciences
Leadiant BiosciencesMD - Rockville
1 program
STP206PHASE_11 trial
Active Trials
NCT01954017Completed103Est. Oct 2018
Parexel
ParexelMA - Boston
1 program
ST266PHASE_1_2

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
Infant Bacterial TherapeuticsIBP-9414
Infant Bacterial TherapeuticsIBP-9414
BioTherapeutics IncST266
Leadiant BiosciencesSTP206
Autonomous Therapeuticsthermostatic feeding
Human BioScienceslaparotomy

Clinical Trials (6)

Total enrollment: 2,797 patients across 6 trials

NCT03978000Infant Bacterial TherapeuticsIBP-9414

IBP-9414 for the Prevention of Necrotizing Enterocolitis - The Connection Study

Start: Jul 2019Est. completion: Jul 20242,158 patients
Phase 3Unknown
NCT02472769Infant Bacterial TherapeuticsIBP-9414

IBP-9414 for the Prevention of Necrotizing Enterocolitis

Start: May 2016Est. completion: Aug 2017120 patients
Phase 2Completed
NCT06315738BioTherapeutics IncST266

Study to Assess the Safety, Tolerability, and Preliminary Efficacy of ST266 in Infants With Necrotizing Enterocolitis (NEC)

Start: Aug 2024Est. completion: Nov 202936 patients
Phase 1/2Recruiting
NCT01954017Leadiant BiosciencesSTP206

STP206 for the Prevention of Necrotizing Enterocolitis (NEC)

Start: Jan 2014Est. completion: Oct 2018103 patients
Phase 1Completed
NCT06908239Autonomous Therapeuticsthermostatic feeding

Milk Temperature Control and Necrotizing Enterocolitis Risk in Extremely Preterm Infants

Start: Sep 2024Est. completion: Dec 2029250 patients
N/AActive Not Recruiting
NCT00252681Human BioScienceslaparotomy

Comparison of Two Surgical Treatments for Necrotizing Enterocolitis in Human Infants

Start: Jul 1999Est. completion: Jun 2005130 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 2,797 patients
7 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.